Company Profile
Virios Therapeutics Stock Price, News & Analysis
- Ticker:
- VIRI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for VIRI.
Company overview
Business overview
Virios Therapeutics is a biotechnology company focused on viral-trigger and inflammation biology, with an emphasis on chronic disease programs. Its story is built around a narrow disease hypothesis and early-stage development.
Geographic Base and Sector Classification
Virios is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotechnology.
Business Model Characteristics
The company depends on clinical progress, translational validation, and capital efficiency. Investors usually watch early data and whether the company can sustain a coherent thesis.
Position Within the Biotechnology Landscape
Virios occupies a speculative small-cap biotech niche. It is highly dependent on whether its disease hypothesis can survive in the clinic.
Future catalysts
The cleaner way to frame Virios Therapeutics right now is around its latest development priorities. The most useful line from the latest update is Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026. That should keep the program at the center of the company narrative for now. The partnership angle also matters here, especially around “Furthermore, we executed a global development license for our legacy combination antiviral assets.” The Company currently has enrolled 164 patients in its Halneuron ® Phase 2b....
Recent news
- 01
- 02
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Source: Virios Therapeutics
- 03
- 04
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
Source: Virios Therapeutics
- 05
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Source: Virios Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Virios Therapeutics do?
Virios Therapeutics is a biotechnology company focused on viral-trigger and inflammation biology, with an emphasis on chronic disease programs. Its story is built around a narrow disease hypothesis and early-stage development.
On which exchange is VIRI stock listed?
Virios Therapeutics (VIRI) is associated with NASDAQ, United States, Biopharma.
What is Virios?
The cleaner way to frame Virios Therapeutics right now is around its latest development priorities.
Which conditions is Virios Therapeutics targeting with Virios?
Virios Therapeutics is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Virios Therapeutics describe recent progress with Virios?
The cleaner way to frame Virios Therapeutics right now is around its latest development priorities.
What is Therapeutics?
Virios Therapeutics is a biotechnology company focused on viral-trigger and inflammation biology, with an emphasis on chronic disease programs.
What should investors watch for with Therapeutics?
The cleaner way to frame Virios Therapeutics right now is around its latest development priorities.
What is Halneuron?
The most useful line from the latest update is Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026.